Home Cart Sign in  
Chemical Structure| 1360614-48-7 Chemical Structure| 1360614-48-7

Structure of Necrosulfonamide
CAS No.: 1360614-48-7

Chemical Structure| 1360614-48-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Necrosulfonamide is a necroptosis inhibitor that selectively targets the mixed lineage kinase domain-like protein (MLKL), preventing the MLKL-RIP1-RIP3 necrosome complex from interacting with its downstream effectors. MLKL is a critical substrate of RIP3 during necrosis induction.

Synonyms: NSA

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Necrosulfonamide

CAS No. :1360614-48-7
Formula : C18H15N5O6S2
M.W : 461.47
SMILES Code : O=C(NC1=CC=C(S(=O)(NC2=NC=CN=C2OC)=O)C=C1)/C=C/C3=CC=C([N+]([O-])=O)S3
Synonyms :
NSA
MDL No. :MFCD02370191
InChI Key :FNPPHVLYVGMZMZ-XBXARRHUSA-N
Pubchem ID :1566236

Safety of Necrosulfonamide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • MLKL

In Vitro:

Cell Line
Concentration Treated Time Description References
Bel-7402 and SMMC-7721 cells 1 µM Inhibition of necroptosis Cell Death Discov. 2021 Apr 16;7(1):83.
primary neuronal cells 5 µM 14 days NSA markedly reduced PFFs-induced neuronal cell death Mol Neurodegener. 2023 Dec 1;18(1):94.
B16 melanoma cells 1 μM 24 h To evaluate the effect of NSA on cell death, results showed that NSA did not inhibit cell death induced by erastin or RSL3 Pharmacol Res. 2023 Oct;196:106899.
RAW264.7 cells 10 μM 4 h To detect cell death in the necroptosis pathway, results showed that the NSA inhibitor could partially reduce PrsA-induced cell death Virulence. 2023 Dec;14(1):2249779.
human monocytes 5 µM 3, 6, 12, 24 hpi Inhibits pMLKL membrane translocation, prevents H7N9-induced monocyte cell death Cell Death Dis. 2019 Jun 5;10(6):442.
Caco-2 cells 1 µM 1 h Treatment with necrosulfonamide resulted in a decrease in SpvB-mediated cell death, indicating that SpvB promotes necroptosis through MLKL phosphorylation. Cell Death Discov. 2022 Feb 2;8(1):44.
primary MEF cells 5 µM 24 h NSA exhibited neuroprotective effects against 6-OHDA plus TNF-α-induced cell death Mol Neurodegener. 2023 Dec 1;18(1):94.
mPDAC cells 1 μM 24 h To evaluate the effect of Necrosulfonamide on ferroptosis, results showed that Necrosulfonamide had no significant effect on ferroptosis Nat Commun. 2021 Jan 28;12(1):647.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Myocardial ischemia-reperfusion injury model Intraperitoneal injection 20 mg/kg Once daily for 3 weeks NSA treatment significantly reduced plasma cTnT, CK-MB, and LDH content in KO mice with I/R injury, suggesting ameliorated cardiac damage. Redox Biol. 2024 Dec;78:103400
Mice PANC1 or MIAPaCa2 xenograft models Intraperitoneal injection 10 mg/kg Once every other day for 2 weeks To evaluate the effect of Necrosulfonamide on the anticancer activity induced by ferroptosis, results showed that Necrosulfonamide had no significant effect on ferroptosis Nat Commun. 2021 Jan 28;12(1):647.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.17mL

0.43mL

0.22mL

10.83mL

2.17mL

1.08mL

21.67mL

4.33mL

2.17mL

References

 

Historical Records

Categories